SG11201804220SA - Activated stem cells and systemic treatment methods for infected wounds - Google Patents

Activated stem cells and systemic treatment methods for infected wounds

Info

Publication number
SG11201804220SA
SG11201804220SA SG11201804220SA SG11201804220SA SG11201804220SA SG 11201804220S A SG11201804220S A SG 11201804220SA SG 11201804220S A SG11201804220S A SG 11201804220SA SG 11201804220S A SG11201804220S A SG 11201804220SA SG 11201804220S A SG11201804220S A SG 11201804220SA
Authority
SG
Singapore
Prior art keywords
international
colorado
stem cells
activated
pct
Prior art date
Application number
SG11201804220SA
Inventor
Steven W Dow
Lyndah Chow
Valerie Johnson
Original Assignee
Univ Colorado State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado State Res Found filed Critical Univ Colorado State Res Found
Publication of SG11201804220SA publication Critical patent/SG11201804220SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... ..sr.1 15 June 2017(15.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/100328 Publication Al Number (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 35/00 (2006.01) A61P 17/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 35/12 (2015.01) A61P 31/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2016/065392 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 7 December 2016 (07.12.2016) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/264,077 7 December 2015 (07.12.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: COLORADO STATE UNIVERSITY RE- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, SEARCH FOUNDATION [US/US]; P.O. Box 483, Fort LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Collins, Colorado 80522 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: DOW, Steven W.; 8 Blue Grouse Ridge Road, GW, KM, ML, MR, NE, SN, TD, TG). Littleton, Colorado 80127 (US). CHOW, Lyndah; 2457 Declarations under Rule 4.17: Forecastle Dr, Fort Collins, Colorado 80524 (US). JOHN- - as to applicant's entitlement to apply for and be granted a SON, Valerie; 808 East Laurel Street, Fort Collins, Color- patent (Rule 4.170) ado 80524 (US). Published: (74) Agents: STOCK, Christina K. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, Dis- — with international search report (Art 21(3)) trict Columbia 20004 (US). of — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, amendments (Rule 48.2(h)) protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 1-1 .4t GC ei M O O 1-1 N 1-1 C:= (54) Title: ACTIVATED STEM CELLS AND SYSTEMIC TREATMENT METHODS FOR INFECTED WOUNDS ei 0 (57) : Provided herein are compositions containing an infusion ready population of activated, allogeneic mesenchymal stem ,1 . cells and one or more pharmaceutically acceptable carriers, diluents, or excipients. Also provided are methods of treating infected wounds in mammals by administering an effective amount of activated mesenchymal stem cells to the mammal.
SG11201804220SA 2015-12-07 2016-12-07 Activated stem cells and systemic treatment methods for infected wounds SG11201804220SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264077P 2015-12-07 2015-12-07
PCT/US2016/065392 WO2017100328A1 (en) 2015-12-07 2016-12-07 Activated stem cells and systemic treatment methods for infected wounds

Publications (1)

Publication Number Publication Date
SG11201804220SA true SG11201804220SA (en) 2018-06-28

Family

ID=57570663

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804220SA SG11201804220SA (en) 2015-12-07 2016-12-07 Activated stem cells and systemic treatment methods for infected wounds

Country Status (7)

Country Link
US (2) US11185560B2 (en)
EP (1) EP3386521A1 (en)
JP (1) JP7168448B2 (en)
KR (1) KR20180101375A (en)
CN (1) CN108883134A (en)
SG (1) SG11201804220SA (en)
WO (1) WO2017100328A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580678B2 (en) 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device
US10722540B1 (en) 2016-02-01 2020-07-28 The Regents Of The University Of California Microfluidic device and method for shear stress-induced transformation of cells
JP7072228B2 (en) 2016-06-08 2022-05-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and equipment for treating tissues and cells
CN108922620A (en) * 2018-06-20 2018-11-30 南华大学 A kind of surgery cut infection risk evaluating system
CN115087729B (en) * 2020-01-21 2024-06-28 辽宁天安生物制药股份有限公司 Use of rhodococcus ruber cell wall skeleton in regeneration medicine
US20230301977A1 (en) * 2020-09-16 2023-09-28 Agency For Science, Technology And Research Wound healing model
WO2022155068A1 (en) * 2021-01-12 2022-07-21 Colorado State University Research Foundation Cellular-antimicrobial combination composition and methods for treatment of bacterial infections of joints and soft tissues

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR100717724B1 (en) * 2006-01-18 2007-05-14 부산대학교 산학협력단 Composition for the differentiation of mesenchymal stem cells and differentiation method of mesenchymal stem cells using it
US20140017787A1 (en) * 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
KR102555611B1 (en) 2016-03-31 2023-07-13 샌바이오, 인크. Medium, methods, cells and secreted factors for stem cell culture and therapy

Also Published As

Publication number Publication date
JP2018536010A (en) 2018-12-06
US11185560B2 (en) 2021-11-30
US20220047641A1 (en) 2022-02-17
JP7168448B2 (en) 2022-11-09
EP3386521A1 (en) 2018-10-17
WO2017100328A1 (en) 2017-06-15
KR20180101375A (en) 2018-09-12
US20180360885A1 (en) 2018-12-20
CN108883134A (en) 2018-11-23

Similar Documents

Publication Publication Date Title
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201811237WA (en) Combination therapies
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201808909WA (en) Ex vivo bite-activated t cells
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201805001UA (en) Method of treating influenza a
SG11201811580SA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch